1 / 58

Pulmonary Hypertension

Pulmonary Hypertension. Kazemi.toba,M.D . Birjand University of Medical Sciences 24 th Ordibeheshte 1390. Outline. Introduction, definition Pathophysiology Diagnosis Laboratory Findings Idiopathic Pulmonary Arterial Hypertension Natural History Treatment. Introduction.

myra-christian
Download Presentation

Pulmonary Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary Hypertension Kazemi.toba,M.D.Birjand University of Medical Sciences 24thOrdibeheshte 1390

  2. Outline Introduction, definition Pathophysiology Diagnosis Laboratory Findings Idiopathic Pulmonary Arterial Hypertension Natural History Treatment

  3. Introduction • Pulmonary hypertension: • an abnormal elevation in pulmonary artery pressure • result of left heart failure, pulmonary parenchymal or vascular disease, thromboembolism, or a combination of these factors. • Regardless the etiology of pul.htn, it is a feature of advanced disease. • it is essential that the etiology underlying the pulmonary hypertension be clearly determined before treatment. • Corpulmonale : • RV enlargement secondary to any underlying cardiac or pulmonary disease. • Pulmonary hypertension is the most common cause of corpulmonale. Advanced corpulmonale is associated with the development of RV failure.

  4. Cor pulmonale

  5. DEFINITION  The definition of pulmonary hypertension (PH) is based upon right heart catheterization measurements. PH is defined as a mean pulmonary artery pressure greater than 25 mmHg at rest. A mean pulmonary artery pressure of 8 to 20 mmHg at rest is considered normal,.

  6. Pathophysiology Dilated RV- Intact pericardium  RAP   Intrapericardial pressure (IPP)   LV transmural filling pressure= LVEDP-IPP + Shift of IV septum toward LV   LV preload and  LVdistensibility   Systemic Cardiac Output

  7. Pathophysiology • The ability of the RV to adapt to increased vascular resistance is influenced by several factors, including age and the rapidity of the development of pulmonary hypertension • Acute:  RV afterload,  EDV,  EF, SV of RV • Chronic: progressive systolic pressure overload of RV that dilates and hypertrophies, gradual RV dysfunction • venous return compromises RV preload and pulm blood flow • Coexisting hypoxemia can impair the ability of the ventricle to compensate

  8. Pathogenesis of Pulmonary Arterial Hypertension IRREVERSIBLE DISEASE REVERSIBLE DISEASE NORMAL

  9. Symptoms of PH • Dyspnea 60% • Fatigue 19% • Near syncope/syncope 13% • Chest pain 7% • Palpitations 5% • Leg edema 3%

  10. Physical Exam • JVD • Loud P2 (increases PAP) • Left parasternallift (RV heave=R sided overload) • murmur of TR • S3 gallop (advanced RV failure) • CLEAR lungs

  11. Signs of Disease Severity • Dyspnea at rest • Low cardiac output with metabolic acidosis • Hypoxemia • Signs of right heart failure (large V wave on jugularis vein, periph edema, hepatomegaly) • Syncope (poor prognosis) • Chest pain (2 to RV ischemia)

  12. Diagnosis • CXR: Enlarged proximal pulmonary vessels,” • ECG: RAD, RAE, RVH most common • Echo :Estimate PA pressure Assess for shunts and valvular disease; ventricular function

  13. Often suggestive of RVH and RAE ECG Findings

  14. RAE,RVH

  15. central Pul arterial and/or RV enlargement , distal “pruning” Chest X-ray Findings

  16. . Note the dilated proximal pulmonary arteries with a relative lack of pulmonary vasculature in the periphery. No cardiomegaly is noted .

  17. Chest roentgenogram from a patient with primary pulmonary hypertension showing the marked dilation of the main pulmonary arteries and right ventricular enlargement.

  18. Pulmonary hypertension. Chest radiograph in a patient with secondary pulmonary hypertension reveals enlarged pulmonary arteries. This patient was found to have an atrial septal defect.

  19. Severe right chamber dilation • Estimate PA pressure • Assess for shunts • and valvular disease • ventricular function

  20. secondary pulmonary hypertension

  21. Degree of disease Mild Moderate Severe Mean PAP (mmHg) 25 - 40 41 - 55 >55 Severity of Pulmonary Hypertension

  22. Right Heart Cath • Essential for firm diagnosis: • Helps to not dx people with PAH that do not have it! • Vasoreactivity testing • NO, Adenosine—drop in mPAP by 10 mmHg to value < 40 mmHg • Predicts CCB response • Evaluate for septal defects • Shed light on the issue of diastolic dysfunction • Interpret data in context of patient’s volume status

  23. Lab Exam • Selected labs • ANA, RF, ESR • LFTs, hepatitis serologies • HIV antibody • Drugs (cocaine)

  24. Algorithm for investigation of suspected PH

  25. Complications of PH • Right-sided heart failure (corpulmonale). • Blood clots. • Arrhythmia. Irregular heartbeats from the upper or lower chambers of the heart are complications of pulmonary hypertension. These can lead to palpitations, dizziness or fainting and can be fatal. • Bleeding. Pulmonary hypertension can lead to bleeding into the lungs and hemoptysis.

  26. Classification Group 1 "Pulmonary arterial hypertension". • 1. Idiopathic (IPAH) • 2. Familial (FPAH) • 3. Associated with (APAH): • Collagen vascular disease • Congenital systemic-to-pulmonary shunts • Portal hypertension • HIV infection • Drugs and toxins • Other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) • 4. Associated with significant venous or capillary involvement • Pulmonary veno-occlusive disease (PVOD) • Pulmonary capillary hemangiomatosis (PCH) • 5. Persistent pulmonary hypertension of the newborn

  27. Classification • Group 2 : "Pulmonary venous hypertension". Examples: • 1. Left-sided atrial or ventricular heart disease • 2. Left-sided valvular heart disease • Group 3 PH — "Pulmonary hypertension associated with disorders of the respiratory system or hypoxemia". Examples: • 1. Chronic obstructive pulmonary disease • 2. Interstitial lung disease • 3. Sleep-disordered breathing • 4. Alveolar hypoventilation disorders • 5. Chronic exposure to high altitude • 6. Development abnormalities

  28. Classification • Group 4 PH — "Pulmonary hypertension caused by chronic thrombotic or embolic disease". Examples: • 1. Thromboembolic obstruction of proximal pulmonary arteries • 2. Thromboembolic obstruction of distal pulmonary arteries • 3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign material) • Group 5 PH — These patients have PH caused by inflammation, mechanical obstruction, or extrinsic compression of the pulmonary vasculature (eg, sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels by adenopathy, and fibrosingmediastinitis).

  29. Pulmonary Hypertension: Define Lesion Post-Capillary PH (PCWP>15 mmHg; PVR nl) PAH Respiratory Diseases PE Atrial Myxoma Cor Triatriatum MV Disease PV LA RA LV PA VC RV Ao PC LVEDP Systemic HTN AoV Disease PV compression PVOD Pre-capillary PH PCWP<15 mmHg PVR > 3 Wu Myocardial Disease DCM,HCM,ischemic CM RCM,Obesity , others

  30. Idiopathic PH PPH uncommon, incidence : 2 cases per million. female predominance presenting in the 4th and 5th decades although the age range is from infancy to >60 years. Familial PAH :20% of cases of IPAH autosomal dominant inheritance

  31. Natural History of PPH The natural history of IPAH is uncertain the disease is typically diagnosed late Prior to current therapies, a survival of 2–3 years from the time of diagnosis Functional class remains a strong predictor of survival, patients who are in NYHAfunctional class IV having a mean survival of <6 months. The cause of death is usually RV failure, which is manifest by progressive hypoxemia, tachycardia, hypotension, and edema

  32. Mediators of PH Prostacycline Thromboxane A2 Endothelin-1 Nitric Oxide (NO) Serotonin Adrenomedullin Vasoactive Intestinal Peptide (VIP) Vascular Endothelial Growth Factor (VEGF)

  33. Prostacycline & Thromboxane A2 Prostacycline Vasodilator Inhibits platelet activation Antiproliferative properties Thromboxane A2 Vasoconstrictor Platelet agonist in PH balance shifted to Thromboxane A2

  34. ENDOTHELIN-1 Potent vasoconstrictor Stimulates proliferation of smooth muscle cells in PA Plasma levels increased in PHT Level inversely proportional to pulmonary blood flow & CO - ? Direct effect

  35. NO & serotonin NO Vasodilator & inhibitor of platelet activation & vascular SM proliferation Serotonin Vasoconstrictor promoting SM hyperplasia & hypertrophy Elevated plasma levels/ reduced platelet levels in PHT

  36. Goals of Therapy • Alleviate symptoms, improve exercise capacity and quality of life • Improve cardiopulmonary hemodynamics and prevent right heart failure • Delay time to clinical worsening • Reduce morbidity and mortality

  37. Classes of therapy • Medical • Diuretics • Coumadin (IPAH, Anorexigen) • Oxygen • PAH specific therapy • Surgical therapy • Atrial septostomy • Lung transplantation

  38. PAH Therapy: Life style considerations • Sodium restriction • Abstinence from smoking • Avoid high altitude • <4,000 feet above sea level • Avoid physical exertion in setting of pre- or frank syncope sx • Avoid pregnancy

  39. Mainstay of treatment

  40. ANTICOAGULANTS Warfarin Anticoagulant therapy is advocated for all patients with PAH . warfarin increases survival of patients with PAH. The dose of warfarin is generally titrated to achieve an INR of 2–3 times control.

  41. Algorithm for Assessment of Vasoreactivity in Patients with PAH Right Heart CatheterizationWith Acute Vasoreactivity Testing(iNO, epoprostenol, adenosine) mPA 10 mmHg  mPA < 40 mmHg Non - responder Responder (<15%) and candidate for CCB (no RHF) Consider p.o. Bosentan Consider p.o. Sildenafil Consider Inhaled Iloprost Consider s.q. Treprostinil Consider Continuously-Infused Epoprostenol Hemodynamically-Monitored Trial of Calcium Channel BlockerTherapy

  42. Calcium Channel Blockers Patients who have substantial reductions in PAP in response to vasodilators at the time of cardiac catheterization (a fall of 10 mmHg in mean PAP and a final mean pressure <40 mmHg) should be treated with CCB. dramatic reductions in PAP, PVR,improved symptoms, regression of RV hypertrophy improved survival documented to exceed 20 years patients require high doses (e.g., nifedipine, 240 mg/d, or amlodipine, 20 mg/d). <20% of patients respond to CCB in the long term. should not be given to patients who are unresponsive, as they can result in hypotension, hypoxemia, tachycardia, and worsening right heart failure

  43. Endothelin Receptor Antagonists Bosentan :nonselective endothelin receptor antagonist approved treatment of PAH for patients who are NYHA functional classes III and IV. bosentan improved symptoms and exercise tolerance Therapy is initiated at 62.5 mg bid for 1 month,then increased to 125 mg bid . Because of the high frequency of abnormal hepatic function tests associated with drug use, primarily an increase in transaminases, it is recommended that liver function be monitored monthly throughout the duration of use. Bosentan is also contraindicated in patients who are on cyclosporine or glyburide concurrently.

  44. PHOSPHODIESTERASE INHIBITORS • Sildenafil • PDE type5 inhibitor • Reduce metabolism of cGMP • Sildenafil should not be given to patients who are taking nitrate compounds • lowers pulmonary artery pressure and inhibits pulmonary vascular growth • sildenafil improves symptoms and exercise tolerance in PAH • The recommended dose is 20 mg tid. The most common side effect is headache

More Related